Program
nor-ursodeoxycholic acid
Also written as “norucholic acid”, “norUrsodeoxycholic Acid” and “norUrsodeoxycholic acid”.
Its studies are mostly in Cholangitis, Sclerosing · Non-alcoholic Fatty Liver Disease, led by Dr. Falk Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dr. Falk Pharma | 33 open or running | phase 3since Mar 8, 2019 | Mar 8, 2019 | Sep 2027phase 3 · NCT06886360 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2019First study: phase 3 study in Cholangitis, SclerosingFirst studyNCT03872921 · 303 enrolled · Austria, Germany
- Oct 6, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05083390 · 363 planned · Austria
- Mar 14, 2025Phase 3 study in Cholangitis, SclerosingNCT06886360 · 120 planned
Ahead
- Sep 2027Primary completion: phase 3 study in Cholangitis, SclerosingNCT06886360
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06886360Cholangitis, Sclerosing | 3 | Not yet recruiting | Sep 2027 | 120 |
| NCT05083390Non-alcoholic Fatty Liver Disease · Austria | 2 | Recruiting | Jan 2025 | 363 |
| NCT03872921Cholangitis, Sclerosing · Austria, Germany | 3 | Active, not recruiting | Jan 2025 | 303 |
How it is read
Names in the registry
- “norucholic acid”, 1 entry
- “norUrsodeoxycholic Acid”, 1 entry
- “norUrsodeoxycholic acid”, 1 entry
Conditions, from the studies’ own filings
- Cholangitis, Sclerosing, 2 studies
- Non-alcoholic Fatty Liver Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.